Therefore, the phase II BYLieve trial evaluated patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor plus an AI and alpelisib continued to show efficacy in combination with fulvestrant [38]. Here, ERBB2 is linked to breast carcinoma.